NZ597075A - 1, 2, 4-thiazolidin-3-one derivatives as AMP-activated protein kinase (AMPK) agonists for treating cancer - Google Patents

1, 2, 4-thiazolidin-3-one derivatives as AMP-activated protein kinase (AMPK) agonists for treating cancer

Info

Publication number
NZ597075A
NZ597075A NZ597075A NZ59707510A NZ597075A NZ 597075 A NZ597075 A NZ 597075A NZ 597075 A NZ597075 A NZ 597075A NZ 59707510 A NZ59707510 A NZ 59707510A NZ 597075 A NZ597075 A NZ 597075A
Authority
NZ
New Zealand
Prior art keywords
ampk
thiazolidin
agonists
derivatives
protein kinase
Prior art date
Application number
NZ597075A
Other languages
English (en)
Inventor
Jacob Westman
Allan Hallett
Jan Vagberg
Original Assignee
Baltic Bio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baltic Bio Ab filed Critical Baltic Bio Ab
Publication of NZ597075A publication Critical patent/NZ597075A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ597075A 2009-07-08 2010-07-08 1, 2, 4-thiazolidin-3-one derivatives as AMP-activated protein kinase (AMPK) agonists for treating cancer NZ597075A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21373509P 2009-07-08 2009-07-08
PCT/GB2010/001315 WO2011004162A2 (en) 2009-07-08 2010-07-08 Compounds useful as medicaments

Publications (1)

Publication Number Publication Date
NZ597075A true NZ597075A (en) 2013-03-28

Family

ID=43086401

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ597075A NZ597075A (en) 2009-07-08 2010-07-08 1, 2, 4-thiazolidin-3-one derivatives as AMP-activated protein kinase (AMPK) agonists for treating cancer

Country Status (24)

Country Link
US (2) US9162994B2 (enExample)
EP (1) EP2451794B1 (enExample)
JP (1) JP5982281B2 (enExample)
KR (1) KR101765957B1 (enExample)
CN (1) CN102596923B (enExample)
AU (1) AU2010270030B2 (enExample)
BR (1) BR112012000370B1 (enExample)
CA (1) CA2767291C (enExample)
DK (1) DK2451794T3 (enExample)
EA (1) EA026674B1 (enExample)
ES (1) ES2567753T3 (enExample)
HR (1) HRP20160353T1 (enExample)
HU (1) HUE027263T2 (enExample)
IL (1) IL216723A (enExample)
ME (1) ME02443B (enExample)
MX (1) MX337516B (enExample)
NZ (1) NZ597075A (enExample)
PL (1) PL2451794T3 (enExample)
RS (1) RS54718B1 (enExample)
SG (1) SG177558A1 (enExample)
SI (1) SI2451794T1 (enExample)
SM (1) SMT201600225B (enExample)
WO (1) WO2011004162A2 (enExample)
ZA (1) ZA201108901B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100931145B1 (ko) * 2008-07-04 2009-12-10 현대자동차주식회사 조정식 킥 다운 스위치의 조작기구
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ampkを活性化させるインダゾール化合物
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
WO2017210545A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
KR102218333B1 (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
EP3571193B1 (en) 2017-01-23 2021-12-01 Cadent Therapeutics, Inc. Potassium channel modulators
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
MX2021004647A (es) 2018-10-22 2021-08-16 Novartis Ag Formas cristalinas de moduladores de los canales de potasio.
WO2020095010A1 (en) * 2018-11-05 2020-05-14 Balticgruppen Bio Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects
CN109879808B (zh) * 2019-03-05 2020-10-16 北京工业大学 一种含五元唑类杂环基查尔酮类衍生物及制备方法和医药用途
GB201910092D0 (en) 2019-07-15 2019-08-28 Balticgruppen Bio Ab New formulations
GB201910093D0 (en) 2019-07-15 2019-08-28 Balticgruppen Bio Ab New formulations
GB201915094D0 (en) * 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
ES3075388T3 (en) 2019-10-18 2026-08-04 Betagenon Ab New formulations
GB202015585D0 (en) * 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202100352D0 (en) * 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods
GB202112529D0 (en) 2021-09-02 2021-10-20 Betagenon Bio Ab New compounds
JP2026526085A (ja) 2023-07-20 2026-08-05 ベタゲノン アーベー 代謝非柔軟性により誘発される心筋症の治療方法
CN122421964A (zh) 2023-07-20 2026-07-17 塔吉农有限责任公司 使用双重ampk激活剂和线粒体解偶联剂调节血糖水平的方法
CN121925257A (zh) 2023-08-03 2026-04-24 塔吉农有限责任公司 用pdk抑制剂4-氯-n-(2-(4-氯苄基)-3-氧代-2,3-二氢-1,2,4-噻二唑-5-基)苯甲酰胺治疗癌症
WO2025252672A1 (en) 2024-06-03 2025-12-11 Betagenon Ab Use of tryptophan and metabolites thereof as biomarkers for treatment methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093624A (en) 1977-01-31 1978-06-06 Icn Pharmaceuticals, Inc. 1,2,4-Thiadiazolidine-3,5-dione
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
DE60129222T2 (de) 2000-05-11 2008-03-06 Consejo Superior de Investigaciónes Científicas Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
WO2006045581A1 (en) * 2004-10-21 2006-05-04 Neuropharma, S.A. The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
US20090156644A1 (en) 2005-07-21 2009-06-18 Jacob Westman Use of thiazole derivatives and analogues in the treatment of cancer
WO2008090356A1 (en) 2007-01-25 2008-07-31 Betagenon Ab Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity

Also Published As

Publication number Publication date
IL216723A (en) 2017-09-28
BR112012000370A2 (pt) 2016-11-22
US20160128993A1 (en) 2016-05-12
AU2010270030A1 (en) 2012-01-12
WO2011004162A3 (en) 2011-03-03
JP2012532854A (ja) 2012-12-20
US9675596B2 (en) 2017-06-13
KR101765957B1 (ko) 2017-08-07
ES2567753T3 (es) 2016-04-26
JP5982281B2 (ja) 2016-08-31
ZA201108901B (en) 2017-08-30
SI2451794T1 (sl) 2016-05-31
US9162994B2 (en) 2015-10-20
HK1170485A1 (zh) 2013-03-01
CN102596923A (zh) 2012-07-18
IL216723A0 (en) 2012-03-01
BR112012000370B1 (pt) 2019-04-16
MX2012000441A (es) 2012-04-19
EA201200102A1 (ru) 2012-08-30
EP2451794B1 (en) 2016-01-27
KR20120054568A (ko) 2012-05-30
SG177558A1 (en) 2012-02-28
EP2451794A2 (en) 2012-05-16
CA2767291C (en) 2020-01-28
AU2010270030B2 (en) 2015-12-24
DK2451794T3 (en) 2016-03-14
SMT201600225B (it) 2016-08-31
RS54718B1 (sr) 2016-08-31
ME02443B (me) 2016-09-20
HUE027263T2 (en) 2016-10-28
CN102596923B (zh) 2015-04-29
PL2451794T3 (pl) 2016-07-29
MX337516B (es) 2016-03-09
EA026674B1 (ru) 2017-05-31
US20120183537A1 (en) 2012-07-19
CA2767291A1 (en) 2011-01-13
HRP20160353T1 (hr) 2016-05-06
WO2011004162A2 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
IN2012DN02081A (enExample)
MX336381B (es) Boronatos como inhibidores de arginasa.
NZ590550A (en) Inhibitors of Apoptosis (IAP) for treating cancer
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
TW200714604A (en) Substituted heterocycles and the uses thereof
NZ596571A (en) Pyrazolopyrimidines and related heterocycles as kinase inhibitors
WO2010000364A8 (de) Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
NZ597517A (en) 5-fluoropyrimidinone derivatives
MX368346B (es) Derivados de 1,6- diazabiciclo [3.2,1] octano-7-ona y su uso en el tratamiento de las infecciones bacterianas.
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
NZ706506A (en) Heterocyclic compounds and uses thereof
MX2009013341A (es) Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina.
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
MX2010006203A (es) Derivados de pirazol y uso de los mismos como inhibidores de cinasas dependientes de ciclina.
MY176944A (en) Substituted pyrimidines for the treatment of diseases such as cancer
MX349550B (es) 1,7-diazacarbazoles y metodos de uso.
AU2009282962A8 (en) Compounds as kinase inhibitors
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
EP1973407A4 (en) SPIRO COMPOUNDS AND METHODS OF USE
NZ708928A (en) Mannose derivatives for treating bacterial infections
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
NZ594186A (en) Indole derivatives as anticancer agents
MX342947B (es) Tratamiento de diabetes tipo 2.

Legal Events

Date Code Title Description
PSEA Patent sealed
S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 JUL 2017 BY CPA GLOBAL

Effective date: 20140522

S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2018 BY CPA GLOBAL

Effective date: 20170525

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2019 BY CPA GLOBAL

Effective date: 20180524

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2020 BY CPA GLOBAL

Effective date: 20190523

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2021 BY CPA GLOBAL

Effective date: 20200521

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2022 BY CPA GLOBAL

Effective date: 20210527

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2023 BY RENEWALS TEAM

Effective date: 20220707

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2024 BY ENVOY

Effective date: 20230704

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2025 BY ENVOY

Effective date: 20240701

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2026 BY REGIS DE BOISE

Effective date: 20250704